Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.

Publication Year: 2022

DOI:
10.1007/s00134-022-06811-0

PMCID:
PMC9463324

PMID:
35833959

Journal Information

Full Title: Intensive Care Med

Abbreviation: Intensive Care Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Critical Care

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflicts of interestFPW received research funding from Boeringher-Ingelheim, Astrazeneca, Vifor pharmaceuticals, and Whoop, Inc. SH leads a research and training center that receives educational funding from Pfizer Inc. MJM received research funding to her institution from Athersys, Inc, Biomarck Inc, and Quantum Leap Healthcare Collaborative for work unrelated to this manuscript. All other authors have nothing to disclose. Role of the funder/sponsorThe funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Ethics approvalSubjects are enrolled with a waiver of timely informed consent with approval of the institutional review board (IRB) of the University of Pennsylvania (IRB #808542). Subjects or their surrogates are approached as soon as possible for consent, and if consent is not obtained, all biospecimens and data are discarded. Consent to participateSubjects are enrolled with a waiver of timely informed consent with approval of the IRB of the University of Pennsylvania (IRB #808542). Subjects or their surrogates are approached as soon as possible for consent, and if consent is not obtained, all biospecimens and data are discarded. Consent to publishNot applicable/all data used for the present study have been anonymized, and the submission does not include information that may identify individual persons. Conflicts of interest FPW received research funding from Boeringher-Ingelheim, Astrazeneca, Vifor pharmaceuticals, and Whoop, Inc. SH leads a research and training center that receives educational funding from Pfizer Inc. MJM received research funding to her institution from Athersys, Inc, Biomarck Inc, and Quantum Leap Healthcare Collaborative for work unrelated to this manuscript. All other authors have nothing to disclose."

Evidence found in paper:

"Funding This study was supported by grants from the NIH (S10OD025172), NIDDK (K08DK124658, R01DK111638, R01DK113191, P30DK079310), NHLBI (R01HL137006, R01HL137915, K24HL155804, R01HL155159), and AHRQ (R01HS027626)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025